10-K: Dror Ortho-Design Reports Continued Losses in 2024, Focuses on ZSmile Platform Development

Dror Ortho-Design's 2024 annual report reveals ongoing losses as the company invests in its ZSmile platform, a novel approach to teeth alignment.

Summary

• Dror Ortho-Design, Inc. reported a net loss of $5.8 million for the year ended December 31, 2024, compared to a $3.6 million loss in 2023.
• The company is in the development stage and is not generating revenue.
• Dror Ortho-Design is focused on developing its ZSmile platform, an AI-based system for teeth alignment intended for nighttime use.
• The company plans to spend approximately $1 million over the next 12 months on software and hardware development, regulatory approvals, and IP protection.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.
• As of December 31, 2024, the company had approximately $549,000 in cash.
• The company needs to raise additional capital to fund its operations.
• The company is preparing to apply for 510(k) clearance for the ZSmile platform as a Class II medical device.
• The company faces competition from established aligner companies like Align Technologies and Dentsply Sirona.
• The company's stock is not listed on any stock exchange and has a limited market.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with continued losses, reliance on future funding, and auditor concerns about going concern. While the technology is promising, the financial risks outweigh the potential benefits at this stage.

Positives

• The company is developing a novel AI-based platform for teeth alignment.
• The company has several patents for the technology used in the ZSmile platform.
• The company's predecessor product, Aerodentis System, received FDA clearance in 2020.
• The company intends to market its platform in Israel, the European Union, United Kingdom, United States, and Canada.
• The company has a research and development team with experience in software development, medical device development, and data science.

Negatives

• The company is in the development stage and is not generating revenue.
• The company has incurred net operating losses since inception.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company needs to raise additional capital to fund its operations.
• The company's stock is not listed on any stock exchange and has a limited market.
• The company faces competition from established aligner companies.

Risks

• The company's products and technologies may not be accepted by consumers.
• The company may not receive the necessary authorizations to market its platform.
• The company's operations are subject to operating risks, including excess or constrained capacity and operational inefficiencies.
• The company's business could be impacted by major public health issues, political events, trade disputes, war, and terrorism.
• The company's success depends on key executive personnel and relationships with dental professionals.
• The company is subject to various fraud and abuse laws, health information privacy and security laws, and transparency laws.
• The company may be subject to claims that its employees have wrongfully used or disclosed alleged trade secrets of their former employers.
• The company's common stock could be subject to wide fluctuations.

Future Outlook

The company anticipates continuing to incur significant losses as it continues to develop the Platform and intends to spend approximately $1 million over the next 12 months on software and hardware development as well as the accompanying regulatory approvals and IP protection associated with such software and hardware projects.

Industry Context

The dental industry is undergoing rapid digital transformation, with increasing competition in the clear aligner market. Dror Ortho-Design aims to disrupt the market with its AI-based ZSmile platform, offering a discreet and less painful alternative to traditional aligners.

Comparison to Industry Standards

• The report mentions Align Technology, Dentsply Sirona, 3M Clarity Aligners, and Straumann Group as competitors in the clear aligner market.
• The report states that clinical trials demonstrated that Aerodentis System was suitable for adults and pediatric patients with Class 1 and Class 2 malocclusion, including crowding, proclination and retroclination.
• Further, clinical trials have demonstrated that the effectiveness of Aerodentis System was consistent with the results achieved by the Invisalign clear aligners solution provided by Align Technology, Inc.

Related Party Transactions

• The company has entered into consulting agreements with directors Yehuda Englander and Chaim Ravad.
• The company has entered into a consulting agreement with Oriole Avenue Inc., an entity owned by a stockholder of the Company.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment.
• Employees face uncertainty due to the company's financial situation.
• Customers may experience delays or disruptions in product development and availability.
• Suppliers and creditors face the risk of non-payment.

Next Steps

• The company intends to spend approximately $1 million over the next 12 months on software and hardware development as well as the accompanying regulatory approvals and IP protection associated with such software and hardware projects.
• The company is preparing to apply for 510(k) clearance for the ZSmile platform as a Class II medical device.
• The company intends to apply to have its Common Stock listed for trading on The Nasdaq Stock Market.

Key Dates